PBMC gene expression from Crohn's disease patients before Infliximab therapy.. PBMC gene expression from Crohn's disease patients before Infliximab therapy.

About 40% IBD patients treated with anti-TNF antibodies do not respond to therapy. Baseline biomarkers of response are therefore of interest. By combining computational deconvolution of gene expression and meta-analysis approaches we identified cellular biomarkers in tissue (validated in 2 cohorts by IHC of biopsies), and investigated associated gene biomarkers in blood. This dataset provides data from the validation cohort III (blood). Overall design: Whole blood samples were collected from 22 patients diagnosed with Crohn's disease, just before starting anti-TNF therapy (Infliximab). All patients were naive to anti-TNF. Response to therapy was assessed after 14 weeks based on changes in CRP and Calprotectin, as well as endoscopy (Responders: 17; Non-responders: 5). The prognostic power of genes identified to be related to cellular biomarkers identified from meta-analysis of public datasets of biopsy tissues were investigated.

约40%接受抗TNF抗体治疗的炎症性肠病（Inflammatory Bowel Disease, IBD）患者无法获得治疗应答。因此，治疗应答的基线生物标志物成为研究热点。本研究结合基因表达计算反卷积与荟萃分析方法，在组织中鉴定出细胞生物标志物（已通过活检组织免疫组化（Immunohistochemistry, IHC）在2个队列中验证），并对血液中的相关基因生物标志物展开研究。本数据集提供验证队列Ⅲ的血液样本相关数据。研究整体设计：从22例确诊克罗恩病的患者中采集全血样本，采集时机为即将开始抗TNF治疗（英夫利昔单抗，Infliximab）前。所有患者均未接受过抗TNF治疗。治疗14周后，基于C反应蛋白（C-reactive protein, CRP）、钙卫蛋白的变化以及内镜检查结果评估治疗应答情况（应答者17例，无应答者5例）。本研究对从公共活检组织数据集的荟萃分析中鉴定出的、与细胞生物标志物相关的基因的预后价值进行了探究。